The largest database of trusted experimental protocols

Apixaban

Manufactured by Selleck Chemicals
Sourced in United States

Apixaban is a laboratory product manufactured by Selleck Chemicals for research purposes. It is a direct and selective inhibitor of factor Xa, a key component in the blood coagulation cascade. The core function of Apixaban is to inhibit the activity of factor Xa, which plays a crucial role in the formation of blood clots.

Automatically generated - may contain errors

10 protocols using apixaban

1

Caco-2 Proteolytic Activity Assay

Check if the same lab product or an alternative is used in the 5 most similar protocols
Proteolytic activity was measured in Caco-2 cell supernatant samples with BOC-Val-Pro-Arg-amino-4-methylcoumarin hydrochloride (0.5–150 µM, Sigma-Alrich B9395) as substrate in 50 mM Tris, 10 mM CaCl2, 150 mM NaCl, pH = 8.3. Thrombin activity was identified from overall Arg-cleaving enzymes by pre-incubating supernatants with increasing concentrations of the specific thrombin inhibitor lepirudin for 30 min at 37 °C (15.6–1000 pM; Bachem, GmbH), or specific F10 inhibitor Apixaban (0.01 µM, 0.1 µM, 1 µM in 0.1% DMSO vehicle, Selleckchem S1593) for 24-h in serum-free culture medium. Velocity (reaction rate per min) was calculated by the change in fluorescence (excitation: 355 nm, emission: 460 nm), measured over 15 min at 37 °C on a Varioskan Flash microplate reader (Thermo Fisher Scientific). No thrombin activity was detected using this assay in pure FBS nor in heat-inactivated FBS.
+ Open protocol
+ Expand
2

Anticoagulant Agents Evaluation Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Nafamostat mesylate (Tokyo Chemical Industry, Tokyo, Japan), camostat mesylate (Wako, Tokyo, Japan), gabexate mesylate (Tokyo Chemical Industry, Tokyo, Japan), edoxaban, apixaban, rivaroxaban, dabigatran (Selleck Chemicals, Houston, TX, USA), argatroban (Tokyo Chemical Industry, Tokyo, Japan) and darexaban (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
+ Open protocol
+ Expand
3

Activated Protein C Assay with Inhibitors

Check if the same lab product or an alternative is used in the 5 most similar protocols
Bovine thrombin, bovine FXa or human plasma were added to the wells (final volume of 100 µL). For plasma activation, calcium chloride (CaCl2) was added to the plasma (final concentration: 25 mM) and incubated for 10 min in 37 °C. In the relevant wells, the samples were incubated with Protac (Technoclone, 5346212) for 5 min in order to activate PC. Substrate with the inhibitors NAPAP (1 µM, Santa Cruz, sc-208083, Dallas, TX, USA) and apixaban (1 µM, Selleckchem, S1593, Houston, TX, USA) was added and the fluorescence was measured.
+ Open protocol
+ Expand
4

Platelet Activation Assay Protocol

Check if the same lab product or an alternative is used in the 5 most similar protocols
Apixaban (SelleckChem, Houston, TX, USA), D-phenylalanyl-prolyl-arginyl chloromethylketone (PPACK; Essex Junction, VT, USA), adenosine 5’-diphosphate sodium salt (ADP), prostaglandin E1 (PGE1), citrate concentrated solution, and apyrase (Sigma-Aldrich, St. Louis, MO, USA), the GPVI agonist convulxin (Cayman Chemical, Ann Arbor, MI, USA), the TP agonist U46619, the IP agonist iloprost (Tocris Bioscience, Bristol, UK), the PAR4 agonist peptide H-Ala-Tyr-Pro-Gly-Lys-Phe-NH2 trifluoroacetate salt (AYPGKF) and the PAR1 agonist peptide H-Ser-Phe-Leu-Leu-Arg-Asn-OH trifluoroacetate salt (SFLLRN) (Bachem, Torrance, CA, USA), Fluo-4 NW calcium dye and probenecid (Invitrogen, Carlsbad, CA, USA), and FITC mouse anti-human PAC-1, PE mouse anti-human CD62P, and Cy5 Annexin V fluorescent antibodies (BD Biosciences, San Jose, CA, USA) were used and stored according to manufacturers’ instructions. HEPES-buffered saline (HBS, pH 7.4) was prepared with 20 mM N-2-hydroxyethylpiperazine-N’−2-ethanesulfonic acid (HEPES, Fisher Scientific, Fair Lawn, NJ, USA) and 150 mM NaCl (Fisher); Tyrode’s buffer (pH 7.4) was prepared with 10 mM HEPES, 127.2 mM NaCl, 11.9 mM NaHCO3 (Fisher), 5 mM KCl (Fisher), 0.4 mM NaH2PO4 (Fisher), 1 mM MgCl2 · 6 H2O (Sigma), and 5 mM D-glucose (Sigma). Where specified, Ca2+ HBS was prepared by dissolving CaCl2 · 2 H2O in HBS to achieve a calcium concentation of 2 mM.
+ Open protocol
+ Expand
5

Blood Draw with Apixaban Anticoagulant

Check if the same lab product or an alternative is used in the 5 most similar protocols
Whole blood was drawn by venipuncture from healthy donors according to the University of Pennsylvania Institutional Review Board guidelines (protocol number: 805305), into a syringe containing apixaban (SelleckChem) with a final concentration of 250 nM. Donors self-reported to be free of any medications or alcohol use for three days prior to the blood draw. Female donors self-reported to not using oral contraceptives.
+ Open protocol
+ Expand
6

Measurement of Activated Protein C Activity

Check if the same lab product or an alternative is used in the 5 most similar protocols
aPC activity was measured as previously described (Golderman et al., 2020), using a fluorogenic substrate (Pyr-Pro-Arg-AMC, 20 µM; GL Biochem Shanghai Ltd, Shanghai, China). The reactions were carried out in black 96-well microplates (Cat# 237108; Thermo Fisher Scientific, Nunc, Rochester, NY, USA). All reactions were performed in the presence of specific FXa and thrombin inhibitors, apixaban (1 µM; Cat# S1593; Selleckchem, Houston, TX, USA) and NAPAP (1 µM) respectively. Controlled reactions were performed in the presence of phenylmethanesulfonyl fluoride (PMSF, 2 mM, Cat# P7626, Sigma). The cleavage of the substrate was measured at 37°C every 2 minutes over 25 cycles (excitation 360 ± 9 nm, emission 465 ± 20 nm) using microplate reader (Infinite F NANO+; Tecan, Männedorf, Switzerland). The activity was calculated as the linear increase of fluorescence intensity over time. In order to ensure technical accuracy and method validation, a positive control was tested in each and every experiment.
+ Open protocol
+ Expand
7

Anticoagulant Compound Preparation

Check if the same lab product or an alternative is used in the 5 most similar protocols
Apixaban, Betrixaban and Rivaroxaban (Selleckchem) were dissolved in DMSO (according to standard formulations for in vivo experiments) to the final concentration of 10, 4 and 20 mM, respectively.
+ Open protocol
+ Expand
8

Platelet Activation by Apixaban and PPACK

Check if the same lab product or an alternative is used in the 5 most similar protocols
Whole blood (4 μg/mL) CTI was separated into 8 separate 100 μL aliquots. 1 μL samples were drawn at predefined time points (0–35 min) from a single aliquot and added to a well containing 30 nM Apixaban (Selleck Chemicals, Houston, TX) and 100 μM PPACK (Haematologic Technologies) in 100 μL of HBS. An aliquot was briefly mixed before the sample was drawn and discarded immediately after. To measure platelet activation, 20 μg/mL fluorescent fibrinogen (Life Technologies, Grand Island, NY), 1:100 fluorescently labeled anti-P-selectin (Becton Dickson), and 1:100 fluorescently labeled Annexin V (Life Technologies) were added to the diluted whole blood. Samples were incubated for 10 min with the fluorescent labels before reading with the flow cytometer (Accuri C6, Becton Dickson). Positive controls were activated with 5 nM convulxin (Centerchem, Norwalk, CT).
+ Open protocol
+ Expand
9

FXa Activity Assay with Apixaban

Check if the same lab product or an alternative is used in the 5 most similar protocols
The FXa activity assay was based on CS-11(65) chromogenic substrate (Hyphen BioMed). FXa samples with or without apixaban (Selleck Chemicals LLC) were diluted in Tris-BSA buffer pH 7.4 (Hyphen BioMed) containing 5 mM CaCl2 and mixed with substrate (300 µM final concentration [f.c.]) at a ratio of 3:2, and absorbance (410 nm) was measured kinetically on a Biotek Synergy H4 (Agilent Technologies, Inc.) microplate reader at 37 °C.
+ Open protocol
+ Expand
10

Thrombin Generation Assay for FXa Variants

Check if the same lab product or an alternative is used in the 5 most similar protocols
The procoagulant activity of FXa variants (andexanet alfa was purchased from Creative Biomart Inc.) was evaluated using a previously described thrombin generation assay in NPP (Precision BioLogic Inc.)31 (link). Samples were serially diluted in Tris‐BSA buffer and mixed with a recalcified plasma mixture containing plasma (50% vol/vol f.c.), apixaban or rivaroxaban (0.1 µM or 2 µM f.c., both from Selleck Chemicals LLC), platelet substitute in the form of phosphatidyl choline, phosphatidyl serine and sphingomyelin phospholipid vesicles (4 μM f.c.; Phospholipid-TGT®, Rossix), recombinant lipidated TF (2 pM f.c.; RecombiPlasTin, Instrumentation Laboratory), fluorogenic substrate for thrombin ZGGR‐AMC (800 μM f.c.; Bachem) and CaCl2 (12.5 mM f.c.) with a robotic 96‐channel pipettor (ViaFlo 96, Integra Biosciences). Fluorescence was measured at 37 oC using a Biotek Synergy H4 reader, and fluorescence curves were analyzed to obtain the Thrombin Peak Height (TPH) parameter, which was the most representative and responsible parameter of thrombin generation test. The normal TPH range was obtained for human plasma in the absence of inhibitors and FXa variants.
+ Open protocol
+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Sign up for free.
Registration takes 20 seconds.
Available from any computer
No download required

Sign up now

Revolutionizing how scientists
search and build protocols!